Original scientific paper
EFFICACY AND SAFETY OF NPH (NEUTRAL PROTAMINE HAGEDORN) INSULIN COMPARED WITH INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES
PETRA KLANAC
; University of Zagreb School of Medicine, Zagreb, Croatia
MARKO KAŠTELAN
; University of Zagreb School of Medicine, Zagreb, Croatia
IVANA KRALJEVIĆ
; University of Zagreb School of Medicine, Zagreb, Croatia; Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia
TOMISLAV BULUM
; University of Zagreb School of Medicine, Zagreb, Croatia; University of Zagreb School of Medicine, Department of Diabetes, Endocrinology and Metabolic Diseases, University Hospital Merkur, Zagreb, Croatia
ANELA NOVAK
; University of Split School of Medicine, Department of Endocrinology, University Hospital Center Split, Split, Croatia
ANNEMARIE BALAŠKO
; Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia
MAJA JURIĆ SAMARDŽIĆ
; Department of Internal Medicine, General Hospital Slavonski Brod, Slavonski Brod, Croatia
KARIN ZIBAR TOMŠIĆ
; Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia
MAJA BARETIĆ
; University of Zagreb School of Medicine, Zagreb, Croatia; Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia
MAJA MIKOLAJ KIRIĆ
; Department of Internal Medicine, County Hospital Čakovec, Čakovec, Croatia
TANJA MILIČEVIĆ MILARDOVIĆ
; University of Split School of Medicine, Department of Endocrinology, University Hospital Center Split, Split, Croatia
HRVOJE POPOVAC
; Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia
TANJA ŠKORIĆ POLOVINA
; Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia
MARIJA TRIPOLSKI
; Department of Endocrinology, Clinic for Internal Medicine, University Hospital Center Osijek, Osijek, Croatia
TATJANA BAČUN
; Department of Endocrinology, Clinic for Internal Medicine, University Hospital Center Osijek, Osijek, Croatia; Faculty of Medicine, University Josip Juraj Strossmayer in Osijek, Osijek, Croatia
MIRSALA SOLAK
; Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia
SIDBELA ZUKANOVIĆ
; Department of Internal Medicine, General Hospital Slavonski Brod, Slavonski Brod, Croatia
TINA DUŠEK
; University of Zagreb School of Medicine, Zagreb, Croatia; Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia
DARKO KAŠTELAN
; University of Zagreb School of Medicine, Zagreb, Croatia; Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia
*
* Corresponding author.
Abstract
Background: Insulin therapy is often required for achieving adequate glycemic control in patients with type 2 diabetes mellitus (DM2). For that purpose, the insulin analogue glargine is most commonly used in clinical practice, while only a minority of patients
are given the cheaper NPH (Neutral Protamine Hagedorn) human insulin. Methods: In this observational multicenter study we
compared the efficacy and safety of insulin glargine and human NPH insulin. During a six-month follow-up period two groups of
patients with DM2 were observed. One group was administered NPH insulin while insulin glargine was administered in the other
group (53 and 48 participants, respectively). Results: After six months, both patient groups achieved the same hemoglobin A1c
(HbA1c) level (7.5 ± 1 %). In both groups a small statistically nonsignificant increase in body weight was observed. The daily dose of insulin (measured in international units, IU) was significantly higher in the glargine group than in the NPH insulin group (22.4 ± 8.5 IU vs 18.6 ± 7.8 IU). The incidence of hypoglycemia was similar in both groups. Conclusion: Our study revealed no significant difference in the risk of hypoglycemia or in efficacy between insulin glargine and NPH insulin in patients with DM2. Accordingly, our results suggest that human NPH insulin may be an effective and safe treatment for the majority of patients with DM2.
Keywords
type 2 diabetes mellitus; insulin glargine; NPH insulin; hypoglycemia, long-acting insulin
Hrčak ID:
331219
URI
Publication date:
16.5.2025.
Visits: 371 *